Evidence map›Paper›PMID 42019888›Full record

ArticleNeurotoxicology2026

Arsenic attenuates responsiveness to inflammatory stimuli in the SIM-A9 microglial cell line.

Luyu Wang, Lidan Zhao, James Boyett, Duncan Claypool, Amira Adeleke, Sergey Kalinin, Stephanie M Cologna, Douglas L Feinstein, Margaret R Bell, Robert M Sargis

Abstract read
In one paragraph

Article in Neurotoxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luyu WangCollege of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA; Division of Endocrinology, Diabetes, and Metabolism, University of Illinois Chicago, Chicago, IL 60612, USA. Electronic address: lwang240@uic.edu.
Lidan ZhaoCollege of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA; Division of Endocrinology, Diabetes, and Metabolism, University of Illinois Chicago, Chicago, IL 60612, USA. Electronic address: lzhaox@uic.edu.
James BoyettCollege of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA; Division of Endocrinology, Diabetes, and Metabolism, University of Illinois Chicago, Chicago, IL 60612, USA. Electronic address: jboyet2@uic.edu.
Duncan ClaypoolCollege of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA; Department of Bioengineering, University of Illinois Chicago, Chicago, IL 60607, USA. Electronic address: dclayp2@uic.edu.
Amira AdelekeCollege of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA; Division of Endocrinology, Diabetes, and Metabolism, University of Illinois Chicago, Chicago, IL 60612, USA. Electronic address: aadel5@uic.edu.
Sergey KalininCollege of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA; Department of Anesthesiology, University of Illinois, Chicago, IL 60612, USA. Electronic address: sergey@gmail.uic.edu.
Stephanie M ColognaDepartment of Chemistry, University of Illinois Chicago, Chicago IL60607, USA; Laboratory for Integrative Neuroscience, University of Illinois Chicago, Chicago, IL 60607, USA; Department of Biological Sciences, DePaul University, Chicago, IL 60614, USA. Electronic address: cologna@uic.edu.
Douglas L FeinsteinDepartment of Anesthesiology, University of Illinois, Chicago, IL 60612, USA; Chicago Center for Health and Environment, Chicago, IL 60612, USA; Research Service, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60612, USA. Electronic address: dlfeins@uic.edu.
Margaret R BellDepartment of Biological Sciences, DePaul University, Chicago, IL 60614, USA; Department of Health Sciences, DePaul University, Chicago, IL 60614, USA; Chicago Center for Health and Environment, Chicago, IL 60612, USA. Electronic address: margaret.bell@depaul.edu.
Robert M SargisCollege of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA; Division of Endocrinology, Diabetes, and Metabolism, University of Illinois Chicago, Chicago, IL 60612, USA; Chicago Center for Health and Environment, Chicago, IL 60612, USA; Research Service, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60612, USA. Electronic address: rsargis@uic.edu.

Funding

Pilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Briseis A Aschebrook-Kilfoy · 2017 to 2026
$13.6M
Lipid-Based Interventions to Mitigate the Impact of Arsenic on Microglial Function and NeurobehaviorF30ES036896 · NIEHS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Luyu Wang · 2025 to 2026
$110k
NIEHS NIH HHS F30 ES036896NIEHS NIH HHS P30 ES027792
6 · The paper itself

Abstract

Arsenic (As) is a major public health threat, with more than 200 million people at risk of consuming drinking water that exceeds World Health Organization safety guidelines. Given that inorganic arsenic (iAs) is linked to various neuropsychiatric and neurodegenerative disorders, a better understanding of its mechanisms of toxicity is warranted. Current evidence suggests that microglia are central to the pathophysiology of As-induced effects in the central nervous system. Microglia are resident immune cells in the brain that play a crucial role in surveillance, clearance of pathogens, and wound healing. They undergo distinct stages of development throughout life, and their behavior is known to be disrupted by environmental insults such as iAs. To characterize the mechanisms by which iAs alters microglial function, we examined the impact of subtoxic exposure to trivalent inorganic arsenic (As(III)) on microglial activity, both in the presence and absence of immune challenges, using a spontaneously immortalized murine cell line derived from the neonatal cerebral cortex (SIM-A9). Results indicate that iAs causes early activation of SIM-A9 cells through upregulation of toll-like receptor 4-mediated NF-κB signaling, followed by the slower onset of anti-inflammatory effects mediated through increased Nuclear Factor Erythroid 2-related Factor 2 (Nrf2) activity. This later attenuation of responses to inflammatory stimuli suggests that iAs exposure may impair neonatal microglial function and sensitize individuals to secondary challenges relevant to a range of neurological functions and disorders.

Indexed as

ArsenicMicrogliaAnimalsCell LineLipopolysaccharidesMiceNF-E2-Related Factor 2NF-kappa BSignal TransductionToll-Like Receptor 4ArsenicLipopolysaccharidesNF-E2-Related Factor 2NF-kappa BTlr4 protein, mouseToll-Like Receptor 4ArsenicMicrogliaNF-κBNrf2SIM-A9

Identifiers

PMID42019888
PMCPMC13366849

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.